Mapping the de-implementation of traditional diagnostic tests in pediatric acute lymphoblastic leukemia
De‑implementation of cytogenetics in ALL in favor of clinical genomics was successful at SJCRH.
The adoption of clinical genomics at St. Jude Children’s Research Hospital led to the de‑implementation of routine conventional cytogenetics for diagnosing pediatric acute lymphoblastic leukemia (ALL) in 2018. A qualitative study mapped the decision‑making process and identified facilitators, barriers, and lessons learned, concluding that the transition to genomics was successful and improved resource allocation, workflow efficiency, and patient classification without adverse impact on outcomes.
Removing redundant diagnostics can reduce costs, shorten turnaround, and improve precision medicine for pediatric ALL.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT